Tofacitinib as a Possible Treatment for Tacrolimus-Induced Stevens–Johnson Syndrome: A Case Report

Gupta AK , Adamiak A , Chow M . Tacrolimus: A review of its use for the management of dermatoses. J Eur Acad Dermatol Venereol. 2002; 16(2):100–114; doi: 10.1046/j.1468-3083.2002.00380.x

Novack DE , Braskett M , Worswick SD , et al. Drug patch testing in Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review. Ann Allergy Asthma Immunol. 2023; 130(5):628–636; doi: 10.1016/j.anai.2023.01.006

Stern RS , Divito SJ . Stevens-Johnson syndrome and toxic epidermal Necrolysis: Associations, outcomes, and pathobiology-thirty years of progress but still much to be done. J Invest Dermatol. 2017; 137(5):1004–1008; doi: 10.1016/j.jid.2017.01.003

Li M , Liao P-H , Xiang-Zhang G , et al. Tofacitinib for Sjögren syndrome with renal tubular acidosis and psoriasis. Int J Rheum Dis. 2024; 27(1):e14872; doi: 10.1111/1756-185X.14872

National Library of Medicine (US). Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis: Two-arm, Open, Single-center Study. National Library of Medicine (US). Available from: https://clinicaltrials.gov/study/NCT06119490